Vertex Pharmaceuticals Incorporated(VRTX)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
VRTX | 128.16 B | 29.67x | 12.50% | 35.00% | $17.04 | 23.54% | 9.77x | 0.00% | $560.25 | $400.74 |
950160.KQ | 1.37 T | - | - | - | - | - | - | - | $149000.00 | $11470.00 |
ABBV | 479.52 B | 77.31x | 10.20% | 9.80% | $3.51 | - | - | 2.63% | $269.39 | $189.40 |
AMGN | 223.32 B | 26.55x | 9.50% | 22.95% | $15.56 | 91.47% | 4.90x | 2.41% | $447.03 | $280.23 |
950220.KQ | 62.53 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Vertex Pharmaceuticals Incorporated (VRTX) compared to its primary competitors (including 950160.KQ, ABBV, AMGN) reveals distinct metrics. VRTX trades at a valuation discount relative to its competitors, with a P/E ratio of 29.7x versus the peer average of 51.9x (representing a 43% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, VRTX's revenue growth of 12.5% lags behind the peer average of 1526.3%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 35.0% compared to the peer average of 10.9%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• VRTX ranks #2 in P/E ratio, #2 in revenue growth, and #1 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $504.08 | $511.51 | $503.94 | $505.64 | 806,600 | +0.66% |
| 2026-10-06 | $505.00 | $507.41 | $496.33 | $502.31 | 775,000 | -0.24% |
| 2026-10-05 | $504.78 | $506.01 | $496.15 | $503.50 | 914,900 | -0.24% |
| 2026-10-02 | $509.50 | $509.50 | $499.95 | $504.73 | 939,600 | -0.40% |
| 2026-10-01 | $522.39 | $523.52 | $505.27 | $506.74 | 1,194,400 | -3.07% |
| 2026-09-30 | $525.26 | $529.72 | $522.74 | $522.81 | 1,146,000 | -0.74% |
| 2026-09-29 | $522.22 | $529.46 | $519.25 | $526.73 | 688,800 | -0.18% |
| 2026-09-28 | $524.27 | $529.89 | $521.16 | $527.67 | 823,500 | +0.28% |
| 2026-09-25 | $522.55 | $527.69 | $518.92 | $526.19 | 756,200 | +0.73% |
| 2026-09-24 | $515.56 | $528.99 | $515.30 | $522.38 | 940,900 | +1.17% |
| 2026-09-23 | $515.60 | $525.43 | $509.56 | $516.34 | 1,213,700 | +0.26% |
| 2026-09-22 | $521.69 | $525.97 | $508.14 | $514.99 | 1,386,600 | +0.84% |
| 2026-09-21 | $506.85 | $514.10 | $501.01 | $510.72 | 906,500 | +0.47% |
| 2026-09-18 | $516.34 | $518.10 | $505.01 | $508.34 | 2,432,900 | -1.55% |
| 2026-09-17 | $518.35 | $519.07 | $510.20 | $516.34 | 899,600 | +0.60% |
Explore More Analysis for VRTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.